Methods: We reviewed patients with UTUC (n = 712) managed with RNU (2013-2023) and included patients with (1) contrast-enhanced CT < 1 year preoperatively, (2) glomerular filtration rate (GFR) < 3 months preoperatively, and (3) NBGFR 1 to 12 months postoperatively. Predicted NBGFR was 1.25 × (GFRPreRNU) × (SRFContralateral), with 1.25 representing the average renal functional compensation after nephrectomy. For PVA+, differential parenchymal volumes and degree of enhancement were estimated using semiautomated software. SRF-based models (based on PVA+, PVA alone, or nuclear renal scans) and a non-SRF-based algorithm were compared using a 20% accuracy threshold.
Results: Among patients analyzed (n = 352), the median preoperative GFR was 63 mL/min/1.73 m2, 101 (29%) had moderate/severe hydronephrosis, and 42 (12%) had infiltrative renal masses (IRMs). For prediction of NBGFR after RNU, PVA+ demonstrated superior accuracy (84%) compared with PVA alone (accuracy = 79%, P < .05), nuclear renal scans-based approach (accuracy = 73%, P < .01), and non-SRF-based algorithm (accuracy = 65%, P < .01). Among patients with hydronephrosis, notable improvements were observed for PVA+ compared with PVA alone (accuracies 88%/61%, respectively, P ≤ .01). For IRMs, PVA+ seemed to be equivalent to other approaches for predicting NBGFR after RNU.
Conclusions: PVA+ incorporates both differential renal function (degree of enhancement) and parenchymal volumes and outperforms other SRF-based and non-SRF-based approaches for predicting NBGFR after RNU. These findings alleviate concerns that the prevalence of hydronephrosis and IRMs in this population reduces accuracy of SRF-based approaches. PVA+ can inform counseling about the timing of systemic chemotherapy in patients with high-risk UTUC.
Kieran Lewis,1 Jayant Siva,1 Angelica Bartholomew,1 Anne Wong,1 Carlos Munoz Lopez,1 Akira Kazama,1,2 Nityam Rathi,1 Eran N Maina,1 Rebecca A Campbell,1 Nicholas Heller,1 Jason M Scovell,1 Robert Abouassaly,1 Nima Almassi,1 Samuel C Haywood,1 Christopher J Weight,1 Steven C Campbell1
- Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
- Division of Molecular Oncology, Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.